CytomX Therapeutics Inc (CTMX)


Stock Price Forecast

March 15, 2024


Forecasted Returns

7 Days Predict

30 Days Predict

90 Days Predict


Forecasted Market-Excess Returns

7 Days Predict

30 Days Predict

90 Days Predict

Loading CytomX Therapeutics Inc chart...

About the Company

cytomx is an oncology-focused biopharmaceutical company pioneering a novel class of investigational antibody therapeutics based on its probody technology platform. the company uses the platform to create development-stage proprietary cancer immunotherapies against clinically-validated targets, as well as to develop first-in-class investigational cancer therapeutics against novel targets. cytomx believes that its probody platform has the potential to improve the combined efficacy and safety profile of monoclonal antibody modalities, including cancer immunotherapies, antibody drug conjugates and t-cell-recruiting bispecific antibodies. probody therapeutics are designed to take advantage of unique conditions in the tumor microenvironment to enhance the tumor-targeting features of an antibody and reduce drug activity in healthy tissues. investigational probody therapeutics are being developed that address clinically-validated cancer targets in immuno-oncology, such as pd-l1 against which o

CEO

Sean McCarthy

Exchange

NASDAQ

Website

http://cytomx.com/

$101M

Total Revenue

157

Employees

$139M

Market Capitalization

-1.33

Price/Earning ratio

Fundamental Data and Insider Transactions (Quarterly data) Full Screen

Loading the fundamentals chart...

Latest $CTMX News

CytomX Therapeutics Announces Milestone Achievement in PROBODY® T-Cell Engaging Bispecific (TCB) Collaboration with Astellas

14h ago, source: Yahoo Finance

SOUTH SAN FRANCISCO, Calif., March 18, 2024 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field of conditionally activated, localized biologics, today announced that ...

CytomX Therapeutics, Inc. (NASDAQ:CTMX) Q4 2023 Earnings Call Transcript

6d ago, source:

Q4 2023 Earnings Call March 11, 2024 CytomX Therapeutics, Inc. isn’t one of the 30 most popular stocks among hedge funds at ...

CytomX Therapeutics Reports 2023 Financial Results and Provides Business Update

7d ago, source:

CX-904 (EGFRxCD3 T-cell engager) initial Phase 1a dose escalation data in solid tumors anticipated in the 2nd half of 2024 -- CX-2051 (EpCAM ...

CytomX falls as Bristol Myers ends deal for cancer therapy

on MSN ago, source:

CytomX Therapeutics (CTMX) stock fell as Bristol Myers Squibb (BMY) ended their research collaboration for a solid tumor drug ...

CytomX (CTMX) to Report Q4 Earnings: Here's What to Expect

20d ago, source: Hosted on MSN

The company has a four-quarter earnings surprise of 45.44%, on average. CytomX Therapeutics, Inc. Price and EPS Surprise CytomX Therapeutics, Inc. price-eps-surprise | CytomX Therapeutics ...

CytomX Therapeutics Inc (CTMX)

3d ago, source: Investing

As of late, it has definitely been a great time to be an investor in CytomX Therapeutics, Inc. (NASDAQ:CTMX) . The stock has moved higher by 1.7% in the past month, while it is... There was not ...

J.P. Morgan Keeps Their Sell Rating on CytomX Therapeutics (CTMX)

6d ago, source:

In a report released yesterday, Anupam Rama from J.P. Morgan maintained a Sell rating on CytomX Therapeutics (CTMX – Research Report).

CytomX Therapeutics to Present at Upcoming March Investor Conferences

20d ago, source: Nasdaq

SOUTH SAN FRANCISCO, Calif., Feb. 27, 2024 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field of conditionally activated, localized biologics, today announced that ...

CytomX Therapeutics Inc.: CytomX Therapeutics Reports 2023 Financial Results and Provides Business Update

7d ago, source: Finanznachrichten

March 11, 2024 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field of conditionally activated, localized biologics, today reported full year 2023 financial results and ...

Latest Neutral (free) Forecasts

STRONG BUY BUY NEUTRAL SELL STRONG SELL ALL

Loading the latest forecasts...

My Portfolio

Loading your portfolio...